Effect of αvβ3/β5 inhibitor cilengitide on the sensitivity of triple-negative breast cancer and melanoma cell lines to paclitaxel
| Cell Line | Cilengitide |
|---|---|
| MDA-MB-435S | NI |
| MDA-MB-231 | S |
| MDA-MB-468 | R |
| MDA-MB-436 | NI |
| RPMI-7951 | S |
| A375 | S |
| MeWo | R |
NI, no interaction between treatments in combination; R, resistance (decreased sensitivity to combination); S, sensitization (increased sensitivity to combination).